



Gut Dysbiosis: Molecular Mechanisms and Therapies 2.0

Guest Editors:

Dr. Federica Laudisi

Department of Systems Medicine,
University of Rome “Tor Vergata”,
Rome, Italy

Dr. Carmine Stolfi

Department of Systems Medicine,
University of Rome “Tor Vergata”,
00133 Rome, Italy

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editors

Gut dysbiosis—characterized by a reduction in microbial diversity, decreased frequency of beneficial bacterial strains and overgrowth of pathobionts—frequently associates with the development of intestinal and extra-intestinal disorders. Many environmental factors (including diet, drugs and stress) can trigger gut dysbiosis by altering the complex interaction between microbial ecology and the host immune system, thereby promoting intestinal epithelial barrier dysfunctions that may ultimately lead to the development of several pathological conditions.

We invite researchers working on gut dysbiosis to submit original articles or reviews to improve our knowledge on this complex and fascinating field.

- Role of dysbiotic microbiota and microbial metabolites in gut homeostasis, intestinal barrier function and host immune system;
- Contribution of gut dysbiosis to the development of intestinal (e.g., inflammatory bowel diseases, colorectal cancer) and extra-intestinal disorders (e.g., neurological disorders, diabetes);
- Therapeutic strategies for gut microbiota modulation in pathological conditions (e.g., probiotic treatment, fecal microbiota transplantation).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI